MDR_Button Contact_Button News_Button  

CBT-1®  Preclinical

Assay/Test Method

Description

Results

MTT

Cytotoxic assay

Complete modulation

XTT

Cytotoxic assay

Complete modulation

Flow Cytometery

Flourescence

 

 

Inhibition/ efflux

 

 

     -Rhodamine 123

Complete Inhibition

 

     -Calcein

Complete Inhibition

 

     -In Vivo CDX 56

Complete Inhibition

MDR Protein substrates combined CBT-1 ® In Vitro & In Vivo

Doxorubicin

Mitoxantrone

Vinblastine

Vincristine

Etoposide

Taxol

Carboplatin

Daunorubicin

Cytosine

arabinoside

Calcein

Rhodadime 123

Depsipeptide

99M TC-sestamibi

 

 

 

In Vitro Analysis With Doxorubicin (click for chart)

 

 
 
Column Header 1 Column Header 2 Column Header 3
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, was developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant.
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.

 

© CBA Pharma, Inc. 2014 All Rights Reserved Contact Us Privacy Statement Terms and Conditions